



Press release

Dr. Pierre Billardon leaves the Management Board on 30 April 2020

Diana Bachmann appointed as his successor

Erlangen, April 20, 2020 – Dr. Pierre Billardon, since January 2017 CEO and since July 2018 sole member of the Management Board of HumanOptics AG ("Company"), will leave the Company at his own request at the end of his contract which runs until 30 April 2020.

"I have informed the Supervisory Board that I do not wish to accept the offered extension. After three successful and exciting years at HumanOptics, it is now time for me to take on new professional challenges. Due to the growth strategy consistently implemented in recent years and in particular the artificial iris, which received FDA approval at the end of May 2018 and health insurance approval at the end of January 2020 in the USA, the course has been set for the next growth phase of HumanOptics." Dr. Pierre Billardon commented on his decision.

Li Lijuan, Chairperson of the Supervisory Board of the Company, regrets this decision and thanks him on behalf of the Supervisory Board and all employees: "Dr. Pierre Billardon has made a significant contribution to the growth of HumanOptics in recent years. We would like to thank him for his extraordinary commitment and the excellent cooperation at all times. Personally and professionally we wish him all the best and continued success for his future career path".

It is intended that Dr. Pierre Billardon will be succeeded by Diana Bachmann, who has been performing the functional tasks of a CFO since May 2018 alongside Dr. Pierre Billardon as Vice-President Finance & Administration. The Supervisory Board of HumanOptics AG intends to appoint Diana Bachmann with effect from 1 May 2020 initially for a term of office until 31 December 2020 as a member of the Management Board of the Company. Diana Bachmann will pursue the growth strategy of the Company together with the Management Team.

Company profile:

HumanOptics AG (www.humanoptics.com) specializes in the development, production and sale of high-quality implants and accessories for ophthalmic surgery and stands for the highest quality and innovative strength in this segment. The most



important products are intraocular lenses (IOL) for the treatment of cataracts and various forms of ametropia as well as artificial irises. In addition, the company offers the operating ophthalmologists accessories and complementary products as well as comprehensive consulting services. The shares of HumanOptics AG are listed on the Basic Board of the Frankfurt Stock Exchange.

Contact us:

HumanOptics AG
Investor Relations
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0) 9131 50665-0
E-Mail: IR@humanoptics.com